Journals Multiple Sclerosis and related...

Multiple Sclerosis and related Disorders
Zichun Yan, Shiqi Yuan, Qiyuan Zhu, Xiaohua Wang, Zhuowei Shi, Yu Zhang, Jie Liu, Jinzhou Feng, Yiqiu Wei, Feiyue Yin, Shanxiong Chen, Yongmei Li
BACKGROUND: Cognitive impairment (CI) is a common symptom in multiple sclerosis (MS) patients. Cortical damages can be closely associated with cognitive network dysfunction and clinically significant CI in MS. So, in this study, We aimed to develop a radiomics model to efficiently identify the MS patients with CI based on clinical data and cortical damages. METHODS: One hundred and eighteen patients with MS were divided into CI and normal cognitive (NC) cohorts (62/56) as defined by the Montreal Cognitive Assessment (MoCA)...
December 2, 2023: Multiple Sclerosis and related Disorders
Rachid Lotfi, Abdeslam El Kardoudi, Fatiha Chigr
OBJECTIVE: This study aims to describe the clinical, therapeutic, and epidemiological profiles of MS patients in Morocco. METHODS: This descriptive study involved 170 patients representing four Morocco regions. We collected the data using an electronic survey. RESULTS: The results show female dominance in patients with MS. Besides, most patients present with relapsing-remitting MS (RRMS). The main clinical symptoms reported by patients are fatigue, cognitive issues, spasticity, bowel or bladder complaints, and visual issues...
December 2, 2023: Multiple Sclerosis and related Disorders
Malak Alaboudi, Michael Morgan, Alessandro Serra, Hesham Abboud
BACKGROUND: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently defined demyelinating disorder with a rapidly evolving clinical spectrum. Recently, consensus criteria have been proposed (Banwell et al., 2023) to help with disease diagnosis. However, validation of the proposed criteria in real-life MOGAD patients is lacking. In this study, we applied the proposed criteria to an institutional cohort of MOG antibody-positive patients. METHODS: A retrospective study was conducted at a tertiary neuroimmunology clinic from 2018 to 2023...
November 26, 2023: Multiple Sclerosis and related Disorders
Özge Ertekin, Tuğçe Kara, Zuhal Abasıyanık, Turhan Kahraman, Serkan Özakbaş
BACKGROUND: Sedentary behaviour is a major problem in persons with multiple sclerosis (pwMS). However, little is known about the related factors of sedentary behaviour in MS. Our study aimed to examine the association between sedentary behaviour and physical activity level, fear of falling, and fatigue. METHOD: Demographic and clinical data have been recorded. Sedentary behaviour was assessed with the Marshall Sitting Questionnaire, physical activity level was evaluated with the Godin Leisure Time Exercise Questionnaire, fear of falling was evaluated with the Fall Efficacy Scale International, and fatigue was evaluated with the modified fatigue impact scale (MFIS)...
November 25, 2023: Multiple Sclerosis and related Disorders
Yuki Matsumoto, Kunio Tarasawa, Tatsuro Misu, Chihiro Namatame, Yoshiki Takai, Hiroshi Kuroda, Kazuo Fujihara, Kiyohide Fushimi, Kenji Fujimori, Masashi Aoki
BACKGROUND: The real-world data evidences how establishment of neuromyelitis optica (NMO) disease concept and development disease modifying therapy affect the patients with multiple sclerosis (MS) and NMO are lacking. The aim of this study is to clarify the diachronic trend of the severity and admissions of patients with MS and NMO. METHODS: We retrospectively investigated the trends in admissions, treatments, and disabilities in the patients with MS and NMO using the Japanese administrative data between 2012 and 2017...
November 25, 2023: Multiple Sclerosis and related Disorders
Nasim Nehzat, Richard W Browne, Diala Ghazal, Miriam Tamaño-Blanco, Dejan Jakimovski, Bianca Weinstock-Guttman, Robert Zivadinov, Murali Ramanathan
BACKGROUND: Retinol, tocopherols, and carotenoids (RTC) have physiological roles as vitamins, pro-vitamins, and antioxidants, and provide biomarkers of dietary vegetable and fruit intake. The goal was to investigate RTC in multiple sclerosis (MS). METHODS: This exploratory study included 106 people with MS (71 relapsing-remitting MS or RR-MS; and 35 progressive MS or PMS) and 31 healthy controls (HC) at baseline and 5-year follow-up (5YFU). Serum retinol, α-carotene, β-carotene, α-tocopherol, δ-tocopherol, γ-tocopherol, β-cryptoxanthin, lutein/zeaxanthin, and lycopene were measured using high performance liquid chromatography...
November 25, 2023: Multiple Sclerosis and related Disorders
Shishir Dahal, Yohance M Allette, Kerry Naunton, Daniel M Harrison
BACKGROUND: Autopsy data suggests that meningeal inflammation in multiple sclerosis (MS) is driven by CD20+ B-cells. Ocrelizumab is an anti-CD20 monoclonal antibody, and thus could potentially ameliorate meningeal inflammation in MS. Leptomeningeal enhancement (LME) on MRI is suggested as a surrogate biomarker of meningeal inflammation in MS, and thus may be a way of monitoring for this treatment effect. OBJECTIVES: To determine if ocrelizumab impacts meningeal enhancement (ME) on 7T MRI in MS...
November 25, 2023: Multiple Sclerosis and related Disorders
Danya Pradeep Kumar, Tobia Zanotto, Julia S Cozart, Amanda S Bruce, Christie Befort, Catherine Siengsukon, Robin Shook, Sharon Lynch, Rola Mahmoud, Steve Simon, Paul R Hibbing, Betty Drees, Joanie Huebner, Taylor Bradish, Jade Robichaud, Jacob J Sosnoff, Jared M Bruce
BACKGROUND: A majority of the people with multiple sclerosis (pwMS) experience sleep disturbances. Frailty is also common in pwMS. The geriatric literature strongly suggests that frailty is associated with worse sleep outcomes in community-dwelling older adults, but this association has yet to be explored among pwMS. This study focused on examining the association between frailty and sleep quality in pwMS. METHODS: Seventy-six people with both MS and obesity (mean age: 47...
November 24, 2023: Multiple Sclerosis and related Disorders
Bruno Bonfá-Araujo, Mervin Blair, Mariam Elnazali, Joy Kirsten Tolledo, Julie Aitken Schermer, Sarah A Morrow
BACKGROUND: Comprehending the influence of personality traits on functional outcomes in persons with Multiple Sclerosis (pwMS) can aid in tailoring interventions and support strategies. We explored how demographic variables and personality traits predicted current vocation, information processing speed, anxiety and depression symptoms, and disability level in pwMS. METHODS: We used a retrospective chart review on pwMS treated at the London (ON) MS Clinic, that assessed demographic data and personality traits...
November 23, 2023: Multiple Sclerosis and related Disorders
Gagana Mallawaarachchi, David J Rog, Joyutpal Das
BACKGROUND: Multiple Sclerosis (MS) is a neuroinflammatory disorder which affects 2.8 million people world-wide. A growing body of evidence shows ethnic disparities in MS. This review aims to evaluate differences, based upon ethnic background, in the incidence, prevalence, disease course, and efficacy of disease-modifying therapies (DMTs) among people with MS (PwMS). METHOD: Ethnicities were classified as White, Black, Hispanic, Asian, and Middle Eastern and North African (MENA)...
November 22, 2023: Multiple Sclerosis and related Disorders
Venus Pang, Nabil Seery, Robb Wesselingh, Wei Yeh, Michael Zhong, Tracie Tan, Chris Dwyer, Cassie Nesbitt, Louise Rath, Deborah Perera, Francesca Bridge, Olga Skibina, Julian J Bosco, Vilija Jokubaitis, Mark Marriott, Helmut Butkueven, Anneke Van Der Walt, Jennifer Massey, Ian Sutton, Mastura Monif
Ocrelizumab is an anti-CD20 monoclonal antibody (mAb) that has been shown in phase 3 clinical trials to reduce relapses and disease progression in multiple sclerosis (MS) patients. Prior to the approval of ocrelizumab, rituximab, a chimeric anti-CD20 mAb was used to treat MS. Rituximab is still used to treat MS in many countries outside of Australia and remains mainstay of treatment of many non-MS neuroimmunological and systemic inflammatory diseases. Rituximab is currently used in neuromyelitis optica spectrum disorder (NMOSD) and autoimmune encephalitis, in addition to its widespread usage in hematological malignancies and systemic inflammatory diseases...
November 21, 2023: Multiple Sclerosis and related Disorders
Ki Hoon Kim, Su-Hyun Kim, Na Young Park, Min Jeong Kim, Jae-Won Hyun, Ho Jin Kim
BACKGROUND: Latent tuberculosis infection (LTBI) is defined as an immune response to Mycobacterium tuberculosis infection that does not manifest clinically as active tuberculosis (TB). Since some immunotherapies can alter cellular immunity, LTBI screening has been recommended for patients with multiple sclerosis (pwMS) before initiation of long-term immunotherapies. In this study, we investigated the frequency of LTBI in Korean pwMS and patients with neuromyelitis optica spectrum disorder (pwNMOSD) and reported the long-term observation of untreated LTBI under various immunotherapies...
November 21, 2023: Multiple Sclerosis and related Disorders
Ming Meng, Cheng-Yi Zhang, Yong-Mei Li, Ya-Jun Yao, Fu-Qing Zhou, Yu-Xin Li, Ning-Nan-Nan Zhang, De-Cai Tian, Xing-Hu Zhang, Yun-Yun Duan, Ya-Ou Liu
OBJECTIVE: To investigate the abnormal radiomics features of the hippocampus in patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD) and to explore the clinical implications of these features. METHODS: 752 participants were recruited in this retrospective multicenter study (7 centers), which included 236 MS, 236 NMOSD, and 280 normal controls (NC). Radiomics features of each side of the hippocampus were extracted, including intensity, shape, texture, and wavelet features (N = 431)...
November 21, 2023: Multiple Sclerosis and related Disorders
Maddalena Sparaco, Elisabetta Maida, Floriana Bile, Renato Vele, Luigi Lavorgna, Giuseppina Miele, Simona Bonavita
BACKGROUND: The DYSPHAGIA IN MULTIPLE SCLEROSIS (DYMUS) questionnaire is the only specific tool developed to screen for dysphagia in people with Multiple Sclerosis (pwMS). However, some limitations of DYMUS could potentially be addressed by the SWALLOWING DISTURBANCE QUESTIONNAIRE (SDQ), which has not yet been validated in pwMS. The objective of this study was to translate and validate the SDQ into the Italian language for use in pwMS to detect swallowing disturbances. METHODS: We translated the SDQ into Italian and adapted it for use in Italian pwMS...
November 21, 2023: Multiple Sclerosis and related Disorders
Hongzhou Zuo, Li Peng, Wei Li, Yuzhu Wang, Xinyi Du, Xiaoya Zou, Zhaoying Dong, Li Yi, Huimei Yin, Fengying Quan, Oumei Cheng
BACKGROUND AND OBJECTIVE: Epidemiological studies indicate that multiple sclerosis (MS) is associated with epilepsy. However, the causality and directionality of this association remain under-elucidated. This study aimed to reveal the causality between MS and epilepsy. METHODS: A two-sample Mendelian randomization (MR) analysis was performed by using summarized statistics derived from large genome-wide association studies of MS and epilepsy. We used the inverse variance weighted method as the primary approach, and then four other MR methods to bidirectionally evaluate the causality of the association between MS and epilepsy...
November 21, 2023: Multiple Sclerosis and related Disorders
Alaa A Alghanimy, Gavin Giovannoni, Jeanette Lechner-Scott, Michael Levy, E Ann Yeh, Christopher H Hawkes
No abstract text is available yet for this article.
November 20, 2023: Multiple Sclerosis and related Disorders
Mylene Mazerolle, R John Kimoff, Sulaiman Khadadah, Pierre Duquette, Vincent Jobin, Yves Lapierre, Andrea Benedetti, Katarina Majetic, Ann Robinson, Elaine Roger, Amit Bar-Or, Marta Kaminska, Gabriel Leonard, Daria A Trojan
BACKGROUND: Obstructive sleep apnea-hypopnea (OSAH) is common in MS patients and is associated with fatigue. We recently published a randomized, controlled trial (RCT) of active vs sham continuous positive airway pressure (CPAP) treatment in MS patients with fatigue, poor sleep quality, and (OSAH) (Mult Scl J 2022;28:82-92). Our aim was to evaluate the long-term effects of CPAP treatment on fatigue (Fatigue Severity Scale, FSS, primary outcome) and other clinical outcomes in MS patients with OSAH...
November 20, 2023: Multiple Sclerosis and related Disorders
Ahmed Abdelhak, Kai Antweiler, Markus C Kowarik, Makbule Senel, Joachim Havla, Uwe K Zettl, Ingo Kleiter, Muna-Miriam Hoshi, Thomas Skripuletz, Axel Haarmann, Alexander Stahmann, Andre Huss, Stefan Gingele, Markus Krumbholz, Charlotte Selge, Tim Friede, Albert C Ludolph, James Overell, Harold Koendgen, Susanne Clinch, Qing Wang, Ulf Ziemann, Stephen L Hauser, Tania Kümpfel, Ari J Green, Hayrettin Tumani
OBJECTIVES: Detection and prediction of disability progression is a significant unmet need in people with progressive multiple sclerosis (PwPMS). Government and health agencies have deemed the use of patient-reported outcomes measurements (PROMs) in clinical practice and clinical trials a major strategic priority. Nevertheless, data documenting the clinical utility of PROMs in neurological diseases is scarce. This study evaluates if assessment of PROMs could track progression in PwPMS...
November 18, 2023: Multiple Sclerosis and related Disorders
Leticia Rodrigues Gomes, Benito Pereira Damasceno, Brunno Machado de Campos, Alfredo Damasceno
BACKGROUND: Multiple Sclerosis (MS) can impact performance of daily occupations in both relapsing-remitting (RRMS) and secondary-progressive (SPMS) clinical courses. Work force participation decreases with advancing physical disability but the influence of non-motor factors, neuroimaging, and reserve have been scarcely investigated. We aimed to evaluate MRI, clinical, and cognitive (social and general) factors associated with impairment in different daily occupations and address whether cognitive and brain reserve have a positive impact on the ability to maintain these activities...
November 17, 2023: Multiple Sclerosis and related Disorders
Kaitlin E Riegler, John Beauvais, Lindsay O Neto, Elizabeth S Gromisch
While lower resilience has been connected to self-reported sleep problems in persons with multiple sclerosis (PwMS), there has yet to be an examination with diagnosed sleep disorders. This study examined differences in resilience (MS Resiliency Scale) between PwMS with sleep disorders (n = 27), sleep problems (n = 39), and no sleep disorders/problems (n = 46). PwMS with sleep disorders had significantly lower resilience than PwMS with no sleep disorders/problems (p = ...
November 14, 2023: Multiple Sclerosis and related Disorders
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.